Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00266357|
Recruitment Status : Terminated
First Posted : December 16, 2005
Last Update Posted : January 14, 2015
|Condition or disease||Intervention/treatment||Phase|
|Primary Insomnia||Drug: MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose) Drug: Placebo / Duration of Treatment: 2 days for screening period||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||50 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||MK0928 Phase II Sleep Laboratory Study - Primary Insomnia|
|Study Start Date :||November 2005|
|Actual Primary Completion Date :||March 2007|
- Mean of total sleep time over 2 nights.
- Mean of other PSG sleep parameters over 2 nights, mean of subjective sleep parameters, and exploratory residual effect.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00266357
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|